In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders.
Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.
PsychoGenics’ proprietary technologies combine broad in vivo behavioral expertise with robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of Central Nervous System (CNS) disease indications.
Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in helping to identify therapeutic potential for discontinued compounds, and early stage compounds with novel mechanisms of action.